Specialty Pharmacy

Belimumab (Benlysta; GSK) is a B-lymphocyte stimulator-specific inhibiting monoclonal antibody.

Original biologic products, and more recently biosimilar products, are a groundbreaking advancement in modern medical treatments. Pharmacists should understand biologic products and concerns with biosimilars.

Expert discusses how patient support programs, patient assistance programs, and artificial intelligence can help address challenges patients face in access to specialty medications.

Natalie Bedford, senior vice president, US Pharmaceutical Distribution Services at McKesson, discusses the unique challenges of distributing specialty drugs.

Access to certain drugs may be limited through tighter formulary controls and utilization management by Medicare Part D plans dealing with higher costs

Antihemophilic factor (recombinant) Fc-VWF-XTEN fusion protein-ehtl was initally approved in February 2023 for adults and children with hemophilia A for prophylaxis and on-demand treatment to control bleeding.

The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.

The ability to selectively silence or downregulate specific genes has opened new avenues for treating a myriad of diseases.

This is the first FDA advisory committee meeting that will review a potential new posttraumatic stress disorder treatment in 25 years.

Ongoing and active shortages are currently at the highest number since January 2001.

With gene therapy, anti-tissue factor pathway inhibitors, and RNA interference therapy targeting antithrombin, there are many new options that will be available for the patients impacted by hemophilia.

Pharmacists play a multifaceted role beyond dispensing medications, serving as educators, counselors, advocates, and pillars of emotional support for individuals and couples confronting infertility.

Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.

Christie Smith discusses navigating state pharmacy laws and advocating for policy changes to improve patient access and care coordination.

Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

The COVID-19 pandemic spring boarded the evolution of pharmacies toward establishing their position as sites of care.

Venture capital investments in women's health are growing, with innovation looking beyond traditional avenues.

With 50 biosimilar products approved by the FDA, questions arise regarding biosimilar lifecycles and sustainability of the industry.

Sarah Butler discusses the important role pharmacists play in educating patients on these changes in medication prices.

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

Jon Mahrt discusses strategies for improving patient access to medications through affordability initiatives and utilization management of high-cost drugs.

Pharmacists can help patients distinguish between food allergies and intolerances, as well as facilitate access to life-saving medications and preventative care.

Christie Smith discusses a medically integrated dispensing model that aligns the goals of patients, physicians, and pharmacists.

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

At Asembia's AXS24 Summit, a clinician discusses the pathophysiology and classification of pulmonary arterial hypertension.

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

Speakers in a presentation discuss a specific patient with MS who experienced urinary complications and the methods used to treat her.

Tasmina Hydery, PharmD, BCGP, discusses how stakeholders can work together to generate and share real-world evidence on biosimilar effectiveness and switching in order to drive adoption and realize cost savings potential.